11. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Issue 10273 (6th February 2021) Authors: Reich, Kristian; Papp, Kim A; Blauvelt, Andrew; Langley, Richard G; Armstrong, April; Warren, Richard B; Gordon, Kenneth B; Merola, Joseph F; Okubo, Yukari; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Vanvoorden, Veerle; Lebwohl, Mark Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. (17th February 2022) Authors: Griffiths, Christopher E. M.; Papp, Kim A.; Song, Michael; Miller, Megan; You, Yin; Shen, Yaung-Kaung; Han, Chenglong; Blauvelt, Andrew Journal: Journal of dermatological treatment Issue: Volume 33:Number 2(2022) Page Start: 848 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. COVID-19 and Psoriasis: New Guidance From the NPF. Issue 4 (October 2020) Authors: Blauvelt, Andrew Journal: Journal of psoriasis and psoriatic arthritis Issue: Volume 5:Issue 4(2020) Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Delayed wound healing due to increased interleukin‐10 expression in mice with lymphatic dysfunction. Issue 1 (6th May 2013) Authors: Kimura, Takayuki; Sugaya, Makoto; Blauvelt, Andrew; Okochi, Hitoshi; Sato, Shinichi Journal: Journal of leukocyte biology Issue: Volume 94:Issue 1(2013) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry. Issue 3 (30th March 2018) Authors: Siegfried, Elaine C.; Jaworski, Jennifer C.; Eichenfield, Lawrence F.; Paller, Amy; Hebert, Adelaide A.; Simpson, Eric L.; Altman, Emily; Arena, Charles; Blauvelt, Andrew; Block, Julie; Boguniewicz, Mark; Chen, Suephy; Cordoro, Kelly; Hanna, Diane; Horii, Kimberly; Hultsch, Thomas; Lee, James; Le... Journal: Pediatric dermatology Issue: Volume 35:Issue 3(2018) Page Start: 303 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Issue 10348 (23rd July 2022) Authors: Reich, Kristian; Thyssen, Jacob P; Blauvelt, Andrew; Eyerich, Kilian; Soong, Weily; Rice, Zakiya P; Hong, H Chih-ho; Katoh, Norito; Valenzuela, Fernando; DiBonaventura, Marco; Bratt, Tamara A; Zhang, Fan; Clibborn, Claire; Rojo, Ricardo; Valdez, Hernan; Kerkmann, Urs Journal: Lancet Issue: Volume 400:Issue 10348(2022) Page Start: 273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. Issue 9 (September 2018) Authors: Tofte, Susan J.; Papp, Kim; Sadick, Neil; Bohnert, Krista; Simpson, Eric; Thaçi, Diamant; Bieber, Thomas; Blauvelt, Andrew; Sofen, Howard; Gooderham, Melinda; Chen, Zhen; Gadkari, Abhijit; Eckert, Laurent; Graham, Neil M. H.; Pirozzi, Gianluca; Ardeleanu, Marius Journal: Journal of the American Association of Nurse Practitioners Issue: Volume 30:Issue 9(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Issue 10013 (2nd January 2016) Authors: Thaçi, Diamant; Simpson, Eric L; Beck, Lisa A; Bieber, Thomas; Blauvelt, Andrew; Papp, Kim; Soong, Weily; Worm, Margitta; Szepietowski, Jacek C; Sofen, Howard; Kawashima, Makoto; Wu, Richard; Weinstein, Steven P; Graham, Neil M H; Pirozzi, Gianluca; Teper, Ariel; Sutherland, E Rand; Mastey, Vera;... Journal: Lancet Issue: Volume 387:Issue 10013(2016) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Efficacy and safety of mirikizumab in psoriasis: results from a 52‐week, double‐blind, placebo‐controlled, randomized withdrawal, phase III trial (OASIS‐1). (10th August 2022) Authors: Blauvelt, Andrew; Kimball, Alexa B.; Augustin, Matthias; Okubo, Yukari; Witte, Michael M.; Capriles, Claudia Rodriguez; Sontag, Angelina; Arora, Vipin; Osuntokun, Olawale; Strober, Bruce Journal: British journal of dermatology Issue: Volume 187:Number 6(2022) Page Start: 866 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Efficacy and safety of mirikizumab in psoriasis: results from a 52‐week, double‐blind, placebo‐controlled, randomized withdrawal, phase III trial (OASIS‐1). (1st December 2022) Authors: Blauvelt, Andrew; Kimball, Alexa B.; Augustin, Matthias; Okubo, Yukari; Witte, Michael M.; Capriles, Claudia Rodriguez; Sontag, Angelina; Arora, Vipin; Osuntokun, Olawale; Strober, Bruce Journal: British journal of dermatology Issue: Volume 187:Number 6(2022) Page Start: 866 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗